Jeongjun Kim

477 total citations
19 papers, 255 citations indexed

About

Jeongjun Kim is a scholar working on Epidemiology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Jeongjun Kim has authored 19 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 5 papers in Molecular Biology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Jeongjun Kim's work include Lipid metabolism and disorders (5 papers), Phagocytosis and Immune Regulation (5 papers) and Immune cells in cancer (5 papers). Jeongjun Kim is often cited by papers focused on Lipid metabolism and disorders (5 papers), Phagocytosis and Immune Regulation (5 papers) and Immune cells in cancer (5 papers). Jeongjun Kim collaborates with scholars based in South Korea, United States and Netherlands. Jeongjun Kim's co-authors include Michung Yoon, Soon Shik Shin, Haerim Lee, Hyunghee Lee, Jae-Ho Oh, Hwankyu Kang, Yeonhee Hong, Min-Young Kim, Kiyean Nam and Jaeseung Kim and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Jeongjun Kim

19 papers receiving 246 citations

Peers

Jeongjun Kim
Wenlong Zhang China
Hyun‐Jung Jeon South Korea
Atul Shrivastava India
Minyi Qian China
Weibo Wen China
Farahnaz Joukar Iran
Jorge H. Tabares-Guevara Colombia
Wenlong Zhang China
Jeongjun Kim
Citations per year, relative to Jeongjun Kim Jeongjun Kim (= 1×) peers Wenlong Zhang

Countries citing papers authored by Jeongjun Kim

Since Specialization
Citations

This map shows the geographic impact of Jeongjun Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeongjun Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeongjun Kim more than expected).

Fields of papers citing papers by Jeongjun Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeongjun Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeongjun Kim. The network helps show where Jeongjun Kim may publish in the future.

Co-authorship network of co-authors of Jeongjun Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Jeongjun Kim. A scholar is included among the top collaborators of Jeongjun Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeongjun Kim. Jeongjun Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Janssen, Saskia, Caryn M. Upton, Veronique de Jager, et al.. (2025). Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond. American Journal of Respiratory and Critical Care Medicine. 211(8). 1504–1512. 3 indexed citations
2.
Xie, Hao, Anthony B. El-Khoueiry, Angela Alistar, et al.. (2024). A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).. Journal of Clinical Oncology. 42(16_suppl). 3078–3078. 2 indexed citations
3.
Kim, Jeongjun, Tae‐Hwan Kim, Jin‐Ho Choi, et al.. (2023). Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203). Biomedicine & Pharmacotherapy. 167. 115441–115441. 1 indexed citations
4.
Alistar, Angela, Anthony B. El-Khoueiry, Alain C. Mita, et al.. (2023). Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors. Cancer Research. 83(7_Supplement). 2255–2255. 2 indexed citations
5.
Kim, Jeongjun, Jin‐Ho Choi, Hwankyu Kang, et al.. (2022). Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial. Antimicrobial Agents and Chemotherapy. 67(1). e0112322–e0112322. 11 indexed citations
6.
7.
Alistar, Angela, Anthony B. El-Khoueiry, Devalingam Mahalingam, et al.. (2021). A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS2673–TPS2673. 1 indexed citations
8.
Kim, Jeongjun, Jin‐Ho Choi, Hwankyu Kang, et al.. (2021). Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 66(1). e0143621–e0143621. 19 indexed citations
9.
Almeida, Deepak V., Paul J. Converse, Till F. Omansen, et al.. (2020). Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrobial Agents and Chemotherapy. 64(6). 19 indexed citations
10.
Yang, Yeong‐In, Hwankyu Kang, Dongsik Park, et al.. (2020). Abstract 4974: Q702, selective Axl/Mer/CSF1R triple kinase inhibitor enhance the activity of immune checkpoint inhibitor by alteration of immunosuppressive tumor microenvironment. Cancer Research. 80(16_Supplement). 4974–4974. 2 indexed citations
11.
Yang, Yeong‐In, Hwankyu Kang, Jeongjun Kim, et al.. (2019). Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy. Cancer Research. 79(13_Supplement). 4139–4139. 3 indexed citations
12.
Lee, Haerim, Jiwon Ahn, Jeongjun Kim, et al.. (2018). The polyherbal drug GGEx18 from Laminaria japonica, Rheum palmatum , and Ephedra sinica inhibits hepatic steatosis and fibroinflammtion in high-fat diet-induced obese mice. Journal of Ethnopharmacology. 225. 31–41. 21 indexed citations
13.
Kim, Jeongjun, et al.. (2017). The lemon balm extract ALS-L1023 inhibits obesity and nonalcoholic fatty liver disease in female ovariectomized mice. Food and Chemical Toxicology. 106(Pt A). 292–305. 24 indexed citations
14.
Roh, Jong Seong, Haerim Lee, Jeongjun Kim, et al.. (2017). Effect of Gangjihwan on hepatic steatosis and inflammation in high fat diet-fed mice. Journal of Ethnopharmacology. 206. 315–326. 15 indexed citations
15.
16.
Kim, Jeongjun, Hyunghee Lee, Haerim Lee, et al.. (2016). The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long‐Evans Tokushima fatty rats and HepG2 cells. Journal of Ethnopharmacology. 195. 204–213. 14 indexed citations
17.
Lee, Hyunghee, Jeongjun Kim, Yeonhee Hong, et al.. (2015). Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis. PLoS ONE. 10(11). e0141612–e0141612. 30 indexed citations
18.
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenlong Zhang Breakdown of academic impact, for papers by Hyun‐Jung Jeon Breakdown of academic impact, for papers by Atul Shrivastava Breakdown of academic impact, for papers by Minyi Qian Breakdown of academic impact, for papers by Weibo Wen Breakdown of academic impact, for papers by Farahnaz Joukar Breakdown of academic impact, for papers by Jorge H. Tabares-Guevara
Rankless by CCL
2026